References
- Nichol ST, Spiropoulou CF, Morzunov S et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 262(5135), 914–917 (1993).
- MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993–2009. Emerging Infect. Dis. 17(7), 1195–1201 (2011).
- Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, China. Emerging Infect. Dis. 16(8), 1195–1203 (2010).
- Cho HW, Howard CR, Lee HW. Review of an inactivated vaccine against hantaviruses. Intervirology 45(4–6), 328–333 (2002).
- Heyman P, Ceianu CS, Christova I et al. A five-year perspective on the situation of haemorrhagic fever with renal syndrome and status of the hantavirus reservoirs in Europe, 2005–2010. Euro Surveill. 16(36), 1–8 (2011).
- Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23(2), 412–441 (2010).
- Chu YK, Jennings GB, Schmaljohn CS. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69(10), 6417–6423 (1995).
- Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J. Virol. 75(18), 8469–8477 (2001).
- Hukic M, Nikolic J, Valjevac A, Seremet M, Tesic G, Markotic A. A serosurvey reveals Bosnia and Herzegovina as a Europe’s hotspot in hantavirus seroprevalence. Epidemiol. Infect. 138(8), 1185–1193 (2010).
- Balabanova Y, Gilsdorf A, Buda S et al. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS ONE 6(10), e25691 (2011).
- Macneil A, Nichol ST, Spiropoulou CF. Hantavirus pulmonary syndrome. Virus Res. 162(1–2), 138–147 (2011).
- Figueiredo LT, Moreli ML, de-Sousa RL et al.; Viral Diversity Genetic Network Consortium. Hantavirus pulmonary syndrome, central plateau, southeastern, and southern Brazil. Emerging Infect. Dis. 15(4), 561–567 (2009).
- Martinez VP, Bellomo CM, Cacace ML, Suarez P, Bogni L, Padula PJ. Hantavirus pulmonary syndrome in Argentina, 1995-2008. Emerging Infect. Dis. 16(12), 1853–1860 (2010).
- McClain DJ, Summers PL, Harrison SA, Schmaljohn AL, Schmaljohn CS. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 60(1), 77–85 (2000).
- Boudreau EF, Josleyn M, Ullman D et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine 30(11), 1951–1958 (2012).
- Vapalahti K, Paunio M, Brummer-Korvenkontio M, Vaheri A, Vapalahti O. Puumala virus infections in Finland: increased occupational risk for farmers. Am. J. Epidemiol. 149(12), 1142–1151 (1999).
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151–185 (2003).
- Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. Biosocieties 6(1), 34–50 (2011).
- Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 289(1), 6–14 (2001).